Natpar (Parathyroid Hormone)

Parathyroid Hormone, the active ingredient in Natpar, is a parathyroid hormone analog presented as a subcutaneous injectable for use in patients with calcium metabolism disorders. It is employed to manage hypoparathyroidism and osteoporosis by restoring normal serum calcium levels and supporting bone remodeling.

GNH USA supplies Natpar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable cold‑chain logistics for this biologic product.

Natpar acts on the parathyroid hormone pathway to correct calcium imbalance in several clinical settings. - Hypoparathyroidism: restores serum calcium levels and reduces symptoms of hypocalcemia. - Osteoporosis: enhances bone formation and improves bone mineral density. - Calcium metabolism disorders: helps maintain calcium homeostasis in patients with chronic deficiencies.

Natpar may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain: mild discomfort at the subcutaneous injection site. - Nausea: transient feeling of queasiness. - Headache: mild to moderate headache episodes. - Hypercalcemia (mild): slight elevation of serum calcium without symptoms. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Severe hypercalcemia: marked increase in calcium levels that may cause cardiac arrhythmia. - Hypersensitivity reactions: rash, urticaria or anaphylaxis. - Osteosarcoma (rare): potential risk of malignant bone tumor with long‑term use.

Prior to initiating Natpar therapy, several safety considerations should be reviewed. - Monitor serum calcium: check levels regularly to avoid hypercalcemia. - Assess renal function: adjust therapy in patients with impaired kidney function. - Review concomitant calcium or vitamin D supplementation: avoid excessive calcium load. - Avoid use in patients with active hypercalcemia: contraindicated until normalized. - Pregnancy and lactation: limited data, use only if potential benefit justifies risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Natpar can interact with other agents that influence calcium balance or renal handling.

Major Interactions (Avoid): - High‑dose calcium supplements: may cause severe hypercalcemia. - High‑dose active vitamin D analogs (calcitriol): increase risk of calcium overload. - Thiazide diuretics: potentiate calcium retention leading to hypercalcemia.

Moderate Interactions (Monitor Closely): - Loop diuretics: may affect calcium excretion, requiring monitoring. - Bisphosphonates: concurrent use may blunt bone‑forming effects of PTH. - Calcimimetics (e.g., cinacalcet): opposing mechanisms may require dose adjustments.